Oral hepatitis C regimens tackle advanced liver disease PMLiVE Late last week, it was reported that Gilead has reached a deal with Medecins sans Frontieres (MSF) to make the drug available at just $900 per course to countries such as Kenya, Mozambique, Myanmar and India. Please enable JavaScript to view the ... |
